Annual EBIT
-$159.24 M
-$36.06 M-29.27%
December 31, 2023
Summary
- As of February 7, 2025, ALXO annual earnings before interest & taxes is -$159.24 million, with the most recent change of -$36.06 million (-29.27%) on December 31, 2023.
- During the last 3 years, ALXO annual EBIT has fallen by -$115.58 million (-264.70%).
- ALXO annual EBIT is now -1063.52% below its all-time high of -$13.69 million, reached on December 31, 2018.
Performance
ALXO EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$30.26 M
+$8.71 M+22.35%
September 30, 2024
Summary
- As of February 7, 2025, ALXO quarterly earnings before interest & taxes is -$30.26 million, with the most recent change of +$8.71 million (+22.35%) on September 30, 2024.
- Over the past year, ALXO quarterly EBIT has increased by +$20.34 million (+40.19%).
- ALXO quarterly EBIT is now -896.74% below its all-time high of -$3.04 million, reached on September 30, 2019.
Performance
ALXO Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$149.44 M
+$20.34 M+11.98%
September 30, 2024
Summary
- As of February 7, 2025, ALXO TTM earnings before interest & taxes is -$149.44 million, with the most recent change of +$20.34 million (+11.98%) on September 30, 2024.
- Over the past year, ALXO TTM EBIT has dropped by -$4.84 million (-3.35%).
- ALXO TTM EBIT is now -3433.74% below its all-time high of -$4.23 million, reached on March 31, 2019.
Performance
ALXO TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
ALXO EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -29.3% | +40.2% | -3.4% |
| 3 y3 years | -264.7% | -23.4% | -59.3% |
| 5 y5 years | -1063.5% | -113.0% | -183.9% |
ALXO EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -90.8% | at low | -23.4% | +40.2% | -79.0% | +12.0% |
| 5 y | 5-year | -729.9% | at low | -478.1% | +40.2% | -678.8% | +12.0% |
| alltime | all time | -1063.5% | at low | -896.7% | +40.2% | -3433.7% | +12.0% |
ALX Oncology Holdings EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$30.26 M(-22.3%) | -$149.44 M(-12.0%) |
| Jun 2024 | - | -$38.97 M(+10.9%) | -$169.78 M(+3.1%) |
| Mar 2024 | - | -$35.15 M(-22.0%) | -$164.60 M(+3.4%) |
| Dec 2023 | -$159.24 M(+29.3%) | -$45.06 M(-11.0%) | -$159.24 M(+10.1%) |
| Sep 2023 | - | -$50.60 M(+49.8%) | -$144.60 M(+11.8%) |
| Jun 2023 | - | -$33.79 M(+13.4%) | -$129.32 M(+0.7%) |
| Mar 2023 | - | -$29.80 M(-2.0%) | -$128.45 M(+4.3%) |
| Dec 2022 | -$123.18 M(+47.6%) | -$30.41 M(-13.9%) | -$123.18 M(+1.7%) |
| Sep 2022 | - | -$35.32 M(+7.3%) | -$121.15 M(+9.7%) |
| Jun 2022 | - | -$32.92 M(+34.2%) | -$110.41 M(+17.7%) |
| Mar 2022 | - | -$24.53 M(-13.6%) | -$93.79 M(+12.4%) |
| Dec 2021 | -$83.47 M | -$28.39 M(+15.5%) | -$83.47 M(+15.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | -$24.58 M(+50.8%) | -$72.50 M(+25.3%) |
| Jun 2021 | - | -$16.30 M(+14.7%) | -$57.84 M(+9.9%) |
| Mar 2021 | - | -$14.21 M(-18.4%) | -$52.64 M(+20.6%) |
| Dec 2020 | -$43.66 M(+127.6%) | -$17.42 M(+75.6%) | -$43.66 M(+28.5%) |
| Sep 2020 | - | -$9.92 M(-10.6%) | -$33.98 M(+25.4%) |
| Jun 2020 | - | -$11.09 M(+111.9%) | -$27.10 M(+34.2%) |
| Mar 2020 | - | -$5.24 M(-32.3%) | -$20.19 M(+5.2%) |
| Dec 2019 | -$19.19 M(+40.2%) | -$7.73 M(+154.7%) | -$19.19 M(+67.5%) |
| Sep 2019 | - | -$3.04 M(-27.5%) | -$11.45 M(+36.1%) |
| Jun 2019 | - | -$4.19 M(-0.9%) | -$8.42 M(+99.1%) |
| Mar 2019 | - | -$4.23 M | -$4.23 M |
| Dec 2018 | -$13.69 M | - | - |
FAQ
- What is ALX Oncology Holdings annual earnings before interest & taxes?
- What is the all time high annual EBIT for ALX Oncology Holdings?
- What is ALX Oncology Holdings annual EBIT year-on-year change?
- What is ALX Oncology Holdings quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for ALX Oncology Holdings?
- What is ALX Oncology Holdings quarterly EBIT year-on-year change?
- What is ALX Oncology Holdings TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for ALX Oncology Holdings?
- What is ALX Oncology Holdings TTM EBIT year-on-year change?
What is ALX Oncology Holdings annual earnings before interest & taxes?
The current annual EBIT of ALXO is -$159.24 M
What is the all time high annual EBIT for ALX Oncology Holdings?
ALX Oncology Holdings all-time high annual earnings before interest & taxes is -$13.69 M
What is ALX Oncology Holdings annual EBIT year-on-year change?
Over the past year, ALXO annual earnings before interest & taxes has changed by -$36.06 M (-29.27%)
What is ALX Oncology Holdings quarterly earnings before interest & taxes?
The current quarterly EBIT of ALXO is -$30.26 M
What is the all time high quarterly EBIT for ALX Oncology Holdings?
ALX Oncology Holdings all-time high quarterly earnings before interest & taxes is -$3.04 M
What is ALX Oncology Holdings quarterly EBIT year-on-year change?
Over the past year, ALXO quarterly earnings before interest & taxes has changed by +$20.34 M (+40.19%)
What is ALX Oncology Holdings TTM earnings before interest & taxes?
The current TTM EBIT of ALXO is -$149.44 M
What is the all time high TTM EBIT for ALX Oncology Holdings?
ALX Oncology Holdings all-time high TTM earnings before interest & taxes is -$4.23 M
What is ALX Oncology Holdings TTM EBIT year-on-year change?
Over the past year, ALXO TTM earnings before interest & taxes has changed by -$4.84 M (-3.35%)